PATH vs XLO · P/E 19, rev $1.61B vs rev $19.1M
Uipath Inc (PATH) versus Xilio Development Inc (XLO) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Xilio Development Inc (XLO) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported XLO revenue for 2025-09-30 was $19.1M. Net income was -$45.4M. XLO currently screens at market cap $55.3M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. XLO currently screens at market cap $55.3M.
Not investment advice. Open the PATH and XLO stock pages for the full models.
Not investment advice.